Elon Musk has put himself in their crosshairs

Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.

I share with you in this special investigative documentary.

Laura L. Johnson net worth and biography

Laura Johnson Biography and Net Worth

Director of Kura Oncology

Laura Johnson has served as a director since June 26, 2020. Ms. Johnson currently serves as the President and Chief Executive Officer of Next Generation Clinical Research, a contract research organization that Ms. Johnson founded in 1999. Additionally, Ms. Johnson is the President and Chief Executive Officer of Eufaeria Biosciences, Inc., a development biotechnology company that she founded in 2016. Ms. Johnson is also a founder and former member of the board of directors of SB Bancorp, Inc., a financial holding company, and Settlers Bank, Inc., a Wisconsin chartered business bank. In addition, Ms. Johnson has served as a member of the board of directors of La Jolla Pharmaceutical Company (Nasdaq: LJPC), a biopharmaceutical company, since 2013, Odonate Therapeutics (Nasdaq: ODT), a biopharmaceutical company, since 2018, Harmony Hill Farm Sanctuary since 2019 and Agrace HospiceCare from 2013 to 2016. In 2008 and 2010, she was honored as a biotechnology entrepreneur by the national organization, Women in Bio, and in 2008 received the Rising Star Award by the Wisconsin Biotech and Medical Device Association. Most recently, she was the recipient of the Wisconsin Biohealth Business Award at the BioForward Annual Biohealth Summit in October 2019. Ms. Johnson holds a nursing degree from The University of the State of New York-Albany.

What is Laura L. Johnson's net worth?: The estimated net worth of Laura L. Johnson is at least $545,670.59 as of August 21st, 2023. Ms. Johnson owns 33,091 shares of Kura Oncology stock worth more than $545,671 as of November 14th. This net worth evaluation does not reflect any other assets that Ms. Johnson may own. Learn More about Laura L. Johnson's net worth.
How do I contact Laura L. Johnson?: The corporate mailing address for Ms. Johnson and other Kura Oncology executives is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. Kura Oncology can also be reached via phone at (858) 500-8800 and via email at [email protected]. Learn More on Laura L. Johnson's contact information.
Has Laura L. Johnson been buying or selling shares of Kura Oncology?: Laura L. Johnson has not been actively trading shares of Kura Oncology in the last ninety days. Most recently, on Monday, November 22nd, Laura L. Johnson bought 85 shares of Kura Oncology stock. The stock was acquired at an average cost of $25.90 per share, with a total value of $2,201.50. Learn More on Laura L. Johnson's trading history.
Who are Kura Oncology's active insiders?: Kura Oncology's insider roster includes Laura Johnson (Director), Anthony Praill (CFO), and Saiid Zarrabian (Insider). Learn More on Kura Oncology's active insiders.
Are insiders buying or selling shares of Kura Oncology?: In the last twelve months, insiders at the sold shares 5 times. They sold a total of 99,534 shares worth more than $2,004,336.81. The most recent insider tranaction occured on May, 20th when insider Teresa Brophy Bair sold 2,615 shares worth more than $57,922.25. Insiders at Kura Oncology own 5.5% of the company. Learn More about insider trades at Kura Oncology.
Information on this page was last updated on 5/20/2024.

Laura L. Johnson Insider Trading History at Kura Oncology

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
11/22/2021	Buy	85	$25.90	$2,201.50

Laura L. Johnson Buying and Selling Activity at Kura Oncology

Kura Oncology Company Overview

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Today's Range

Now: $16.49

$16.41

$17.93

50 Day Range

MA: $18.63

$16.72

$21.08

2 Week Range

Now: $16.49

$8.80

$24.17

Volume

734,891 shs

Average Volume

895,012 shs

Market Capitalization

$1.28 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86